Relative Activation of Human Pregnane X Receptor versus Constitutive Androstane Receptor Defines Distinct Classes of CYP2B6 and CYP3A4 Inducers
Top Cited Papers
- 1 January 2007
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 320 (1) , 72-80
- https://doi.org/10.1124/jpet.106.112136
Abstract
Both the human pregnane X receptor (hPXR) and constitutive androstane receptor (hCAR) are capable of regulating CYP3A4 and CYP2B6 gene expression. However, the majority of currently identified CYP3A4 and CYP2B6 inducers are confirmed activators of hPXR but not hCAR. To compare these receptors with respect to their chemical selectivities, 16 drugs known to induce CYP3A4 and/or CYP2B expression were evaluated for relative activation of hPXR versus hCAR. Because of the high basal but low chemical-induced activation of hCAR in immortalized cells, alternative methods were used to evaluate hCAR activation potential. Thirteen of the 16 compounds were classified as moderate to strong hPXR activators. In contrast, carbamazepine (CMZ), efavirenz (EFV), and nevirapine (NVP) were classified as negligible or weak hPXR activators at concentrations associated with efficacious CYP2B6 reporter or endogenous gene induction in primary human hepatocytes, suggesting potential activation of hCAR. Subsequent experiments demonstrated that these three drugs efficiently induced nuclear accumulation of in vivo-transfected enhanced yellow fluorescent protein-hCAR and significantly increased expression of a CYP2B6 reporter gene when hCAR was expressed in CAR–/– mice. In addition, using a recently identified, chemically responsive splice variant of hCAR (hCAR3), the hCAR activation profiles of the 16 compounds were evaluated. By combining results from the hPXR- and hCAR3-based reporter gene assays, these inducers were classified as hPXR, hCAR, or hPXR/hCAR dual activators. Our results demonstrate that CMZ, EFV, and NVP induce CYP2B6 and CYP3A4 preferentially through hCAR and that hCAR3 represents a sensitive tool for in vitro prediction of chemical-mediated human CAR activation.Keywords
This publication has 39 references indexed in Scilit:
- Differential Regulation of Hepatic CYP2B6 and CYP3A4 Genes by Constitutive Androstane Receptor but Not Pregnane X ReceptorThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Retinoid X Receptor-α-Dependent Transactivation by a Naturally Occurring Structural Variant of Human Constitutive Androstane Receptor (NR1I3)Molecular Pharmacology, 2005
- Functional analysis of four naturally occurring variants of human constitutive androstane receptorMolecular Genetics and Metabolism, 2005
- Clinical Pharmacokinetics of CyclophosphamideClinical Pharmacokinetics, 2005
- Human Constitutive Androstane Receptor Mediates Induction of CYP2B6 Gene Expression by PhenytoinJournal of Biological Chemistry, 2004
- The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic ActivityThe Journal of Pharmacology and Experimental Therapeutics, 2003
- A Cell-Based Reporter Gene Assay for Determining Induction of CYP3A4 in a High-Volume SystemThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Clinical Pharmacokinetics of Non-Nucleoside Reverse Transcriptase InhibitorsClinical Pharmacokinetics, 2001
- Clinically Significant Pharmacokinetic Drug Interactions with CarbamazepineClinical Pharmacokinetics, 1996
- Clinical Pharmacokinetics of CarbamazepineClinical Pharmacokinetics, 1978